Search results
Results from the WOW.Com Content Network
Levetiracetam, sold under the brand name Keppra among others, is a novel antiepileptic drug [7] used to treat epilepsy. [8] It is used for partial-onset , myoclonic , or tonic–clonic seizures, [ 7 ] and is taken either by mouth as an immediate or extended release formulation or by injection into a vein .
A loading dose is most useful for drugs that are eliminated from the body relatively slowly, i.e. have a long systemic half-life. Such drugs need only a low maintenance dose in order to keep the amount of the drug in the body at the appropriate therapeutic level, but this also means that, without an initial higher dose, it would take a long ...
Similarly, children exposed lamotrigine or phenytoin in the womb do not seem to differ in their skills compared to those who were exposed to carbamazepine. [96] There is inadequate evidence to determine if newborns of women with epilepsy taking anticonvulsants have a substantially increased risk of hemorrhagic disease of the newborn. [94]
Continuing the maintenance dose for about 4 to 5 half-lives (t 1/2) of the drug will approximate the steady state level. [1] One or more doses higher than the maintenance dose can be given together at the beginning of therapy with a loading dose. [2] A loading dose is most useful for drugs that are eliminated from the body relatively slowly ...
The journal is abstracted and indexed in Scopus and the Social Sciences Citation Index.According to the Journal Citation Reports, its 2017 impact factor is 0.959, ranking it 29th out of 40 journals in the category "Education, Special", [1] 51st out of 69 journals in the category "Rehabilitation", [2] and 65th out of 73 journals in the category "Psychology, Developmental".
Classic autism, also known as childhood autism, autistic disorder, or Kanner's syndrome, is a formerly diagnosed neurodevelopmental disorder first described by Leo Kanner in 1943. It is characterized by atypical and impaired development in social interaction and communication as well as restricted, repetitive behaviors, activities, and interests.
The formula for determining the dose is: [1] If there is a single recommended maintenance dose in the literature, this is preferred. If there are a range of recommended maintenance doses then If the literature recommends generally increasing from initial to maximum dose provided it is tolerated, pick the maximum dose.
The Combating Autism Act of 2006 (Public Law No: 109-416) is an Act of Congress public law that was passed by the 109th United States Congress (Senate Bill 843) and was signed into law by President of the United States George W. Bush on December 19, 2006.